France Gene Therapy Market Size & Outlook, 2023-2030
The gene therapy market in France is expected to reach a projected revenue of US$ 1,271.3 million by 2030. A compound annual growth rate of 22.3% is expected of France gene therapy market from 2024 to 2030.
The France gene therapy market generated a revenue of USD 311.5 million in 2023 and is expected to reach USD 1,271.3 million by 2030.
The France market is expected to grow at a CAGR of 22.3% from 2024 to 2030.
In terms of segment, aav was the largest revenue generating vector type in 2023.
AAV is the most lucrative vector type segment registering the fastest growth during the forecast period.
Gene therapy market data book summary
Market revenue in 2023
USD 311.5 million
Market revenue in 2030
USD 1,271.3 million
Growth rate
22.3% (CAGR from 2024 to 2030)
Largest segment
Aav
Fastest growing segment
AAV
Historical data
2018 - 2022
Base year
2023
Forecast period
2024 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Lentivirus, AAV, RetroVirus & gamma RetroVirus, Modified Herpes Simplex Virus, Other Vector Type
Key market players worldwide
Regenxbio Inc, Oxford Biomedical Research, Bristol-Myers Squibb Co, Sanofi SA, Ultragenyx Pharmaceutical Inc, Roche Holding AG ADR, Bluebird bio Inc, Novartis AG ADR, UniQure NV, Cellectis SA, Sangamo Therapeutics Inc, Benitec Biopharma Inc, SiBiono GeneTech, Transgene SA, Gensight Biologics SA, Astellas Pharma Inc
Other key industry trends
In terms of revenue, France accounted for 3.6% of the global gene therapy market in 2023.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Europe, UK gene therapy market is projected to lead the regional market in terms of revenue in 2030.
UK is the fastest growing regional market in Europe and is projected to reach USD 2,470.1 million by 2030.
France is expected to witness significant growth over the forecast period owing to research initiatives focusing on the development of potential treatments for targeted diseases in the region.
Moreover, increasing government initiatives and rising investments in the development of novel gene therapy products in the country are anticipated to support market growth over the forecast period.
In June 2021, Yposkesi’s bio-production project was selected for the French government investment program. It will increase the company’s gene therapy vector capacity through the government’s “Plan de Relance” scheme.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Gene Therapy Market Outlook will help companies and investors design strategic landscapes.
Aav was the largest segment with a revenue share of 38.81% in 2023.
Horizon Databook has segmented the France gene therapy market based on lentivirus, aav, retrovirus & gamma retrovirus, modified herpes simplex virus, other vector type covering the revenue growth of each sub-segment from 2018 to 2030.
France is expected to witness significant growth over the forecast period owing to research initiatives focusing on the development of potential treatments for targeted diseases in the region.
Moreover, increasing government initiatives and rising investments in the development of novel gene therapy products in the country are anticipated to support market growth over the forecast period.
In June 2021, Yposkesi’s bio-production project was selected for the French government investment program. It will increase the company’s gene therapy vector capacity through the government’s “Plan de Relance” scheme.
France Gene Therapy Market Vector Type Outlook (Revenue, USD Million , 2018-2030)
Lentivirus
AAV
RetroVirus & gamma RetroVirus
Modified Herpes Simplex Virus
Adenovirus
Non-viral Plasmid Vector
Other Vector Type
France Gene Therapy Market Indication Outlook (Revenue, USD Million , 2018-2030)
Acute Lymphoblastic Leukemia (ALL)
Inherited Retinal Disease
Large B-cell Lymphoma
ADA-SCID
Melanoma (lesions)
Beta-Thalassemia Major/SCD
Head & Neck Squamous Cell Carcinoma
Peripheral arterial disease
Spinal Muscular Atrophy (SMA)
Others
Reasons to subscribe to Gene Therapy Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Gene Therapy Market Outlook databook
Our clientele includes a mix of Gene Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France Gene Therapy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into France Gene Therapy Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.